

DELPHION

No acti

Select DR

Log Out | Work Files | Saved Searches

RESEARCH

PRODUCTS

INSIDE DELPHION

My Account

Search: Quick/Number Boolean Advanced

Derwent Record

View: Expand Details Go to: Delphion Integrated View

Tools: Add to Work File: Create new

Derwent Title: Compsn. for transdermal admin. of active agents, partic. vitamin D3 - which are lipophilic, comprises lipophilic active agent, silicone-based adhesive polymer compsn., absorption promoter and volatile solvent

Original Title: EP0679392A1: Pharmaceutical form for transdermal administration

Assignee: LAURENT P Individual
LAB LAFON SA L Standard company
Other publications from LAB LAFON SA L (LAFO)...

Inventor: LAURENT P;

Accession/Update: 1995-374953 / 200325

IPC Code: A61K 0/00 ; A61K 9/00 ; A61K 9/06 ; A61K 9/70 ; A61K 31/56 ; A61K 47/30 ; A61K 47/34 ; A61K 6/00 ; A61K 7/021 ; A61K 7/44 ; A61K 9/10 ; A61K 31/59 ; A61K 47/10 ; A61K 47/14 ; A61K 47/32 ; A61L 24/04 ; A61L 25/00 ; A61L 26/00 ;

Derwent Classes: A96; B07; D22; P34;

Manual Codes: A06-A00E3 (Inorganic silicon polymers use as medical, dental, cosmetic and veterinary), A12-V01 (Medicines, pharmaceuticals), B03-G (D (calciferol)), B04-C03D (Natural, other condensation [exc. polyethers]), B12-M02F (Transdermal), D09-C (Bandages, dressings [general and others])

Derwent Abstract: (EP0679392A) Compsn. designed to form a film on the skin for transdermal admin. of an active agent, comprises: a) a lipophilic active agent, b) 5-60 wt.% of a silicone-based adhesive polymer compsn. c) 0-25 wt.% of an absorption promoter, and d) 25-95 wt.% of a volatile solvent.
Use - Use of the compsn. for the transdermal admin. of active agents, pref. vitamin D3, is claimed.
Advantage - The claimed compsn. is simple to make and does not require complex industrial machinery. It is cheap, unlike systems of prior art. It has a range of application and use. Transdermal admin. of active agents has many advantages including reduced side-effects, prolonged use with a constant plasma concn. of active agent which is not degraded by initial passage through the liver or in the digestive tract, and good patient tolerance.

Dwg.0/0

Family:	PDF Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
	<input checked="" type="checkbox"/> EP0679392A1 *	1995-11-02	199549	11	French	A61K 9/70
		Des. States: (R) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE				
		Local appls.: EP1995000400949 Filed:1995-04-26 (95EP-0400949)				
	<input checked="" type="checkbox"/> US6538039 =	2003-03-25	200325	7	English	A61K 47/30
		Local appls.: US1996000741967 Filed:1996-10-31 (96US-0741967)				
		CIP of US1995000428958 Filed:1995-04-26 (95US-0428958)				

HU0221599B1 = 2002-11-28 200309 English A61K 9/70
 Local appls.: Previous Publ. HU00075251 (HU 75251)
HU1995000001245 Filed:1995-04-28 (95HU-0001245)

US20020111387A1 = 2002-08-15 200256 8 English A61K 9/00
 Local appls.:

ES2169746T3 = 2002-07-16 200256 Spanish A61K 9/70
 Local appls.: Based on EP00679392 (EP 679392)
EP1995000400949 Filed:1995-04-26 (95EP-0400949)

DE69524470E = 2002-01-24 200215 German A61K 9/70
 Local appls.: Based on EP00679392 (EP 679392)
DE1995000624470 Filed:1995-04-26 (95DE-0624470)
EP1995000400949 Filed:1995-04-26 (95EP-0400949)

EP0679392B1 = 2001-12-12 200204 10 French A61K 9/70
 Des. States: (R) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 Local appls.: EP1995000400949 Filed:1995-04-26 (95EP-0400949)

TW0448050A = 2001-08-01 200222 XX_XX A61K 31/56
 Local appls.: TW1995000106070 Filed:1995-06-14 (95TW-0106070)

CA2148112C = 2001-01-30 200117 English A61K 47/34
 Local appls.: CA1995002148112 Filed:1995-04-27 (95CA-2148112)

KR0233770B1 = 1999-12-01 200111 English A61K 9/70
 Local appls.: KR1995000010376 Filed:1995-04-28 (95KR-0010376)

JP02740465B2 = 1998-04-15 199820 6 English A61K 9/70
 Local appls.: Previous Publ. JP08059456 (JP 8059456)
JP1995000106274 Filed:1995-04-28 (95JP-0106274)

AU0680731B = 1997-08-07 199740 English A61K 9/70
 Local appls.: Previous Publ. AU09517675 (AU 9517675)
AU1995000017675 Filed:1995-04-28 (95AU-0017675)

HU0075251T = 1997-05-28 199803 English A61K 9/70
 Local appls.: HU1995000001245 Filed:1995-04-28 (95HU-0001245)

NZ0272014A = 1997-05-26 199727 English A61K 9/06
 Local appls.: NZ1995000272014 Filed:1995-04-28 (95NZ-0272014)

ZA9503392A = 1996-12-31 199707 15 English A61K 0/00
 Local appls.: ZA1995000003392 Filed:1995-04-26 (95ZA-0003392)

JP08059456A = 1996-03-05 199619 7 English A61K 9/70
 Local appls.: JP1995000106274 Filed:1995-04-28 (95JP-0106274)

AU9517675A = 1995-11-16 199602 English A61K 9/70
 Local appls.: AU1995000017675 Filed:1995-04-28 (95AU-0017675)

FR2719220A1 = 1995-11-03 199550 10 French A61K 9/00
 Local appls.: FR1994000005272 Filed:1994-04-29 (94FR-0005272)

CA2148112A = 1995-10-30 199611 English A61K 47/34
 Local appls.: CA1995002148112 Filed:1995-04-27 (95CA-2148112)

INPADOC [Show legal status actions](#)
Legal Status:

First Claim: 1. Composition destinée à former sur la peau une pellicule pour l'administration transdermique d'un principe actif, qui comprend :

- a) un principe actif lipophile
- b) de 5 à 60 % en poids d'une composition polymère adhésive à base de silicium
- c) de 0 à 25 % en poids d'un promoteur d'absorption et
- d) de 25 à 95 % en poids d'un solvant volatil.